Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dimethyl Sulfoxide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1333224 | 0.80 | — | — | |
| SCHEMBL1330876 | 0.80 | — | — | |
| SCHEMBL3948099 | 0.80 | TSHR (1.00) | TSHRALDH1A1LMNATP53 | |
| SCHEMBL16123 | 0.80 | — | — | |
| SCHEMBL3775773 | 0.80 | TSHR (1.00) | TSHRALDH1A1LMNATP53 | |
| Butane SCHEMBL10624113 | 0.79 | TSHR (0.69) | TSHRALDH1A1LMNATP53 | |
| SCHEMBL1014110 | 0.77 | — | — | |
| SCHEMBL10783338 | 0.77 | — | — | |
| SCHEMBL991942 | 0.77 | — | — | |
| Bromide SCHEMBL2163421 | 0.77 | TSHR (0.92) | TSHRALDH1A1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114588316-A | Multifunctional mussel-bionic hydrogel | 程豪 | 2022-06-07 | — | — | CN | claimed |
| CN-108721254-B | paclitaxel-N-succinyl hydroxyethyl chitosan polymer drug long-acting sustained-release membrane and preparation method thereof | 昆明医科大学第二附属医院 | 2021-07-30 | — | — | CN | claimed |
| CN-108635340-B | Triamcinolone acetonide high-molecular drug long-acting sustained-release membrane and preparation method thereof | 昆明医科大学第二附属医院 | 2021-07-30 | — | — | CN | claimed |
| CN-117138093-A | Recombinant collagen repair dressing and preparation method thereof | 精妙(广东)生物科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-114588316-A | Multifunctional mussel-bionic hydrogel | 程豪 | 2022-06-07 | — | — | CN | disclosed |
| CN-113358618-A | Exosome capturing method based on surface multi-thorn coding microspheres | 南京鼓楼医院 | 2021-09-07 | — | — | CN | disclosed |
| CN-108635340-B | Triamcinolone acetonide high-molecular drug long-acting sustained-release membrane and preparation method thereof | 昆明医科大学第二附属医院 | 2021-07-30 | — | — | CN | disclosed |
| CN-108721254-B | paclitaxel-N-succinyl hydroxyethyl chitosan polymer drug long-acting sustained-release membrane and preparation method thereof | 昆明医科大学第二附属医院 | 2021-07-30 | — | — | CN | disclosed |
| US-9394379-B2 | Process for producing water-soluble hyaluronic acid modification | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-07-19 | — | — | US | disclosed |
| EP-1790665-B1 | PROCESS FOR PRODUCING WATER-SOLUBLE MODIFIED HYALURONIC ACID | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2014-11-05 | — | — | EP | disclosed |
| US-20120183567-A1 | PROCESS FOR PRODUCING WATER-SOLUBLE HYALURONIC ACID MODIFICATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-07-19 | — | — | US | disclosed |
| US-8143391-B2 | Process for producing water-soluble hyaluronic acid modification | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-03-27 | — | — | US | disclosed |
| US-20090148534-A1 | Process for producing water-soluble hyaluronic acid modification | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-06-11 | — | — | US | disclosed |
| EP-1790665-A1 | PROCESS FOR PRODUCING WATER-SOLUBLE HYALURONIC ACID MODIFICATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090148534-A1 | Process for producing water-soluble hyaluronic acid modification | CD44, HABP2, HPSE | TSHR 3037/4885ALDH1A1 541/4885LMNA 2064/4885 |
| US-20120183567-A1 | PROCESS FOR PRODUCING WATER-SOLUBLE HYALURONIC ACID MODIFICATION | CD44, HPSE, HABP2 | TSHR 2982/4885ALDH1A1 518/4885LMNA 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.